de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol 2022 May 25. pii: 6593129. doi: 10.1093.
PMID: 35639513